MEDVi vs Oak Longevity: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Oak Longevity overall, scoring 7.7/10 vs 7.5/10. Oak Longevity is more affordable at $130/mo vs $299/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.
A side-by-side comparison of MEDVi and Oak Longevity covering pricing, scores, medication types, insurance, and more to help you decide.
MEDVi
#20 of 42MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.
Visit MEDViOak Longevity
#23 of 42Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing — patients pay each month manually rather than auto-renew.
Visit Oak Longevity| Feature | MEDVi | Oak Longevity |
|---|---|---|
| Our Score | 7.7/10 | 7.5/10 |
| Starting Price | $299/mo | $130/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Users who want a low entry price with oral and injectable compounded options | Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin) |
| Ranking | #20 | #23 |
Pros & Cons Compared
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Oak Longevity
Pros
- +$130/mo for compounded semaglutide is among the cheapest entries on the market — Sprout Health ($99) and Sesame Care ($99) are lower, but Oak undercuts most mid-tier platforms
- +Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
- +No-subscription model — patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
- +Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
- +Money-back guarantee if not approved by physician — useful safety net for borderline-eligibility patients
- +Free shipping and free health coaching included in every program
Cons
- −Brand-name pricing ($1,200-$1,500/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo, LillyDirect Zepbound $299/mo. Never buy brand-name through Oak
- −No published lab panels, no specialty (obesity medicine) physicians disclosed — clinical depth is shallow
- −'Up to 50% cheaper than competitors' marketing claim is unverified and inconsistent — depends on which competitor and which medication tier
- −'Longevity' framing pushes users toward add-on products (NAD+, Sermorelin, Tesamorelin) that have limited clinical evidence for weight loss specifically
- −Newer brand without disclosed company history, founding date, or executive team on landing pages
- −Three-month plans are billed upfront — pricing transparency is good, but commit-up-front is a friction point for users testing the platform
Our Verdict
MEDVi edges out Oak Longevity with a score of 7.7/10 vs 7.5/10. If budget is your priority, Oak Longevity starts at $130/mo compared to MEDVi's $299/mo. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).